A PHARMACOKINETIC AND PHARMACOGENOMIC STUDY OF PATIENTS WITH HIGH-GRADE

高级别患者的药代动力学和药物基因组学研究

• 批准号: 7716666
• 负责人: JANA PORTNOW
• 金额: $ 1.8万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-20 至 2008-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7716666
• 关键词: Computer Retrieval of Information on Scientific Projects Database; DNA Methyltransferase; DNA Modification Methylases; Drug Kinetics; Funding; Glioma; Grant; Institution; Methyltransferase Gene; Patients; Pharmacogenomics; Research; Research Personnel; Resources; Single Nucleotide Polymorphism; Source; Standards of Weights and Measures; Thrombocytopenia; United States National Institutes of Health; temozolomide

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The objectives of this study are to compare the pharmacokinetic (PK) profiles of temozolomide (TMZ) in patients who develop severe (grade 3-4) thrombocytopenia to the PK profiles in patients who do not develop severe thrombocytopenia while receiving standard first-line therapy and to determine if patients with high-grade gliomas who develop thrombocytopenia while receiving standard first-line therapy have any single nucleotide polymorphisms in the O 6-methylguianine-DNA methyltransferase (MGMT) gene.

这个子项目是众多研究子项目之一